Edgar Torres Garcia
Endocrinology, Diabetes & Metabolism · Cidra, PRNPI 1871741090
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,234 of the $16,866 with a category attached, or 60.7%. 16 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 40.2% of the total. Reporting peaked in 2019 at $8,177 and has fallen 94.1% since, to $482 in 2025.
Across 341 payments — averaging $49.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$7K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Medtronic$1K
- Johnson & Johnson$1K
- Novo Nordisk$933
- plus $3K from 10 others
What the payments were for
- Consulting fees$7504%
- Speaking & faculty fees$4,47927%
- Travel & lodging$1,3288%
- Food & beverage$10,23461%
- Education$760%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 71 | $6,774 |
| AstraZeneca | 47 | $1,792 |
| Boehringer Ingelheim | 52 | $1,428 |
| Medtronic | 4 | $1,426 |
| Johnson & Johnson | 17 | $1,366 |
| Novo Nordisk | 42 | $933 |
| Amgen(2 entities) | 12 | $745 |
| Merck | 32 | $681 |
| Eli Lilly Export S.A. Puerto Rico Branch | 32 | $649 |
| Bayer | 9 | $405 |
| Abbott | 9 | $284 |
| Lilly USA, LLC | 5 | $195 |
| PBG Puerto Rico LLC | 2 | $55 |
| AbbVie | 3 | $47 |
| Bayer Puerto Rico Inc. | 2 | $46 |
| Dexcom, Inc. | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,866 in reported general payments places this provider in the 85th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Synjardy XrEmpagliflozin/Metformin Hcl | 301 | $216,323 |
| OzempicSemaglutide | 164 | $161,564 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 238 | $156,509 |
| TrulicityDulaglutide | 71 | $70,185 |
| Xigduo XrDapaglifloz Propaned/Metformin | 85 | $53,455 |
| JardianceEmpagliflozin | 67 | $43,615 |
| SynthroidLevothyroxine Sodium | 775 | $41,138 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 39 | $26,949 |
| MounjaroTirzepatide | 22 | $23,748 |
| GlyxambiEmpagliflozin/Linagliptin | 22 | $20,441 |
| FarxigaDapagliflozin Propanediol | 31 | $18,262 |
| JanuviaSitagliptin Phosphate | 21 | $16,751 |
| TradjentaLinagliptin | 11 | $9,930 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $7,810 |
| LantusInsulin Glargine,hum.Rec.Anlog | 44 | $5,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Trijardy Xr, Jardiance, Glyxambi, Tradjenta | $1,428 | $446,818639 claims |
| Novo NordiskOzempic | $933 | $161,564164 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $195 | $97,293107 claims |
| MerckJanumet Xr, Januvia | $681 | $43,70060 claims |
| AbbVieSynthroid | $47 | $41,138775 claims |
| AstraZenecaFarxiga | $1,792 | $18,26231 claims |
| Sanofi-aventis U.S. LLCLantus | $6,774 | $5,63644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Cidra
- Nixzaliz Rodriguez RiveraCidra$6K
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Milliette Alvarado SantiagoRio Piedras$75K
- Altagracia Alcantara GonzalezBayamon$58K
- Jean Pujals KuryBayamon$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.